Studie hodnotící, zda pembrolizumab samotný nebo v kombinaci s CMP-001 zlepšuje účinnost u pacientů s operabilním melanomem
Randomizovaná studie fáze II neoadjuvantního pembrolizumabu samotného nebo v kombinaci s CMP-001 u pacientů s operabilním melanomem: Studie účinnosti a biomarkerů
This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with CMP-001 may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. The addition of CMP-001 to pembrolizumab could improve the ability of the immune system to shrink tumors and to prevent them from returning.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVE:
I. To evaluate the rate of pathologic complete response (pCR) rate in patients in each arm.
SECONDARY OBJECTIVES:
I. To evaluate the rate of pathologic near-complete/major response (pMR) of the neoadjuvant therapy in each arm.
II. To evaluate the pathologic response rate of un-injected lesions on the combination arm (Arm B).
III. To evaluate relapse-free survival (RFS) in each arm. IV. To evaluate overall survival (OS) in each arm. V. To evaluate the preoperative radiographic response rate in each arm. VI. To evaluate safety and toxicity of neoadjuvant therapy in each arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A:
NEOADJUVANT PHASE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.
ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial.
ARM B:
NEOADJUVANT PHASE: Patients receive VLP-encapsulated TLR9 agonist CMP-001 (CMP-001) subcutaneously (SC) on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.
ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up at 30 days and then every 3 months if < 2 years from study entry, every 6 months if 2-5 years from study entry, and every 12 months if > 5 years from study entry for up to 10 years (15 years total follow up).
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Alaska
-
Anchorage, Alaska, Spojené státy, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Spojené státy, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Spojené státy, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Spojené státy, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Spojené státy, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Spojené státy, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Spojené státy, 99508
- Providence Alaska Medical Center
-
Fairbanks, Alaska, Spojené státy, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Tucson, Arizona, Spojené státy, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Spojené státy, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Fort Smith, Arkansas, Spojené státy, 72903
- Mercy Hospital Fort Smith
-
-
California
-
Burbank, California, Spojené státy, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Dublin, California, Spojené státy, 94568
- Epic Care-Dublin
-
Emeryville, California, Spojené státy, 94608
- Bay Area Breast Surgeons Inc
-
Emeryville, California, Spojené státy, 94608
- Epic Care Partners in Cancer Care
-
Martinez, California, Spojené státy, 94553-3156
- Contra Costa Regional Medical Center
-
Oakland, California, Spojené státy, 94609
- Alta Bates Summit Medical Center - Summit Campus
-
Oakland, California, Spojené státy, 94609
- Bay Area Tumor Institute
-
Orange, California, Spojené státy, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Spojené státy, 92868
- Saint Joseph Hospital - Orange
-
Walnut Creek, California, Spojené státy, 94597
- Epic Care Cyberknife Center
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Spojené státy, 80012
- The Medical Center of Aurora
-
Boulder, Colorado, Spojené státy, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Spojené státy, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Denver, Colorado, Spojené státy, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Spojené státy, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Spojené státy, 80220
- Rocky Mountain Cancer Centers-Rose
-
Englewood, Colorado, Spojené státy, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Spojené státy, 80113
- Swedish Medical Center
-
Englewood, Colorado, Spojené státy, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Englewood, Colorado, Spojené státy, 80113
- The Melanoma and Skin Cancer Institute
-
Greeley, Colorado, Spojené státy, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, Spojené státy, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Spojené státy, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Spojené státy, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Spojené státy, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Spojené státy, 80260
- Rocky Mountain Cancer Centers-Thornton
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Spojené státy, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Spojené státy, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Spojené státy, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Spojené státy, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Spojené státy, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Spojené státy, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Spojené státy, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Spojené státy, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Spojené státy, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Spojené státy, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Spojené státy, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Spojené státy, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Spojené státy, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Spojené státy, 60612
- University of Illinois
-
Decatur, Illinois, Spojené státy, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Spojené státy, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Spojené státy, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Spojené státy, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Spojené státy, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Spojené státy, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Spojené státy, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Spojené státy, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Spojené státy, 61455
- Illinois CancerCare-Macomb
-
Mount Vernon, Illinois, Spojené státy, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Spojené státy, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Spojené státy, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Spojené státy, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Spojené státy, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Spojené státy, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Spojené státy, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Spojené státy, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Spojené státy, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Spojené státy, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Spojené státy, 62702
- Springfield Clinic
-
Springfield, Illinois, Spojené státy, 62781
- Springfield Memorial Hospital
-
Washington, Illinois, Spojené státy, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Spojené státy, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic - Ames
-
Boone, Iowa, Spojené státy, 50036
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Spojené státy, 50501
- McFarland Clinic - Trinity Cancer Center
-
Jefferson, Iowa, Spojené státy, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Spojené státy, 50158
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Spojené státy, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Spojené státy, 67530
- Central Care Cancer Center - Great Bend
-
-
Louisiana
-
Baton Rouge, Louisiana, Spojené státy, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Spojené státy, 70809
- Mary Bird Perkins Cancer Center
-
Houma, Louisiana, Spojené státy, 70360
- Terrebonne General Medical Center
-
-
Michigan
-
Battle Creek, Michigan, Spojené státy, 49017
- Bronson Battle Creek
-
Grand Rapids, Michigan, Spojené státy, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Spojené státy, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Spojené státy, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Spojené státy, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Spojené státy, 49048
- Beacon Kalamazoo
-
Muskegon, Michigan, Spojené státy, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Spojené státy, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Spojené státy, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Spojené státy, 49677
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Spojené státy, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Spojené státy, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Spojené státy, 49684
- Munson Medical Center
-
Wyoming, Michigan, Spojené státy, 49519
- University of Michigan Health - West
-
-
Missouri
-
Ballwin, Missouri, Spojené státy, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Spojené státy, 65613
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Spojené státy, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Spojené státy, 63703
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Spojené státy, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Spojené státy, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Spojené státy, 64804
- Freeman Health System
-
Joplin, Missouri, Spojené státy, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Spojené státy, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Spojené státy, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Spojené státy, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Spojené státy, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Spojené státy, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Spojené státy, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Spojené státy, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Spojené státy, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Spojené státy, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Spojené státy, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Missoula, Montana, Spojené státy, 59802
- Saint Patrick Hospital - Community Hospital
-
-
Ohio
-
Beavercreek, Ohio, Spojené státy, 45431
- Indu and Raj Soin Medical Center
-
Centerville, Ohio, Spojené státy, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Spojené státy, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Spojené státy, 45236
- Oncology Hematology Care Inc-Kenwood
-
Dayton, Ohio, Spojené státy, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Spojené státy, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Spojené státy, 45415
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Spojené státy, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Spojené státy, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Spojené státy, 45840
- Orion Cancer Care
-
Franklin, Ohio, Spojené státy, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Spojené státy, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Spojené státy, 45331
- Wayne Hospital
-
Greenville, Ohio, Spojené státy, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Spojené státy, 45429
- Kettering Medical Center
-
Kettering, Ohio, Spojené státy, 45409
- Greater Dayton Cancer Center
-
Springfield, Ohio, Spojené státy, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Spojené státy, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Spojené státy, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Spojené státy, 45373
- Dayton Physicians LLC - Troy
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Bend, Oregon, Spojené státy, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Spojené státy, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Spojené státy, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Spojené státy, 97420
- Bay Area Hospital
-
Newberg, Oregon, Spojené státy, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Spojené státy, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Spojené státy, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Spojené státy, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, Spojené státy, 18045
- Saint Luke's Hospital-Anderson Campus
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, Spojené státy, 18951
- Saint Luke's Hospital-Quakertown Campus
-
Sayre, Pennsylvania, Spojené státy, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
-
South Dakota
-
Aberdeen, South Dakota, Spojené státy, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera Cancer Institute
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Berlin Corners, Vermont, Spojené státy, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Spojené státy, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Aberdeen, Washington, Spojené státy, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Spojené státy, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Spojené státy, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Spojené státy, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Spojené státy, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Spojené státy, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Spojené státy, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Spojené státy, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Spojené státy, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Spojené státy, 98368
- Jefferson Healthcare
-
Seattle, Washington, Spojené státy, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Spojené státy, 98122
- Swedish Medical Center-First Hill
-
Sedro-Woolley, Washington, Spojené státy, 98284
- PeaceHealth United General Medical Center
-
Vancouver, Washington, Spojené státy, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Spojené státy, 99362
- Providence Saint Mary Regional Cancer Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Spojené státy, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Spojené státy, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Medical College of Wisconsin
-
Minocqua, Wisconsin, Spojené státy, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Spojené státy, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Spojené státy, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Spojené státy, 54476
- Marshfield Medical Center - Weston
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patient must be >= 18 years of age
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Patient must have a histologic diagnosis of melanoma belonging to the following American Joint Committee on Cancer (AJCC) 8th edition TNM stages:
- T0, Tx or T1-4; and
- N1b, N2b, N2c, N3b or N3c
-
Patients may have a presentation with primary melanoma with concurrent regional nodal and/or in-transit metastasis; or patients may have a history of primary melanoma or unknown primary melanoma presenting with clinically detected regional nodal and/or in-transit recurrence; and may belong to any of the following groups:
-
Primary cutaneous melanoma with clinically apparent regional lymph node metastases and/or in-transit metastases
-
Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin
-
Primary cutaneous melanoma with concurrent nodal disease involving a single (or multiple) regional nodal group(s) if considered potentially surgically resectable at baseline
-
Clinically detected nodal melanoma (if single site) arising from an unknown primary
-
In-transit cutaneous metastases with or without regional lymph node involvement permitted if considered potentially surgically resectable at baseline
- NOTE: Patients with mucosal and/or uveal melanoma are not eligible for the study
-
-
Patient must be a candidate for definitive surgery and have met with the treating surgical oncologist prior to randomization
-
Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study. Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and COVID-19 (Note: intranasal influenza vaccines, such as Flu-Mist [registered trademark] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events)
-
Patient must have the presence of injectable and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, documented by scans obtained within 4 weeks prior to randomization
- NOTE: Injectable disease is defined as an accessible lesion in the skin, subcutaneous tissue or lymph nodes (LN) close to the skin and palpable by physical examination or approachable with ultrasound guidance
-
Absolute neutrophil count (ANC) >= 1,500 /mcL (obtained within 4 weeks prior to randomization)
-
Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L (obtained within 4 weeks prior to randomization)
-
Platelets >= 100,000 / mcL (obtained within 4 weeks prior to randomization)
-
Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) or measured or calculated creatinine clearance > 60 mL/min (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl] for patients with creatinine levels > 1.5 x institutional ULN) (obtained within 4 weeks prior to randomization)
-
Serum total bilirubin =< 1.5 x institutional ULN; for total bilirubin level > 1.5 x ULN but =< 3 x ULN, the direct bilirubin must be =< the institutional ULN (obtained within 4 weeks prior to randomization)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained within 4 weeks prior to randomization)
-
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization)
-
Activated partial thromboplastin time (aPTT) =< 1.5 x institutional ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (obtained within 4 weeks prior to randomization)
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A urine or serum pregnancy test must be repeated within 72 hours prior to receiving the first dose of pembrolizumab if the test done for eligibility/randomization is done outside of this 72 hour window. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or abstaining from sexual intercourse from time of randomization, while on study treatment, and continue for 26 weeks after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must not have received prior systemic therapy for melanoma including systemic therapy with an anti-PD-1, anti-PD-L1, anti-CTLA-4, BRAF/MEK inhibitor combination and/or TLR-9 agonist
-
Patient must not have a diagnosis of immunodeficiency or be receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization, except as noted here
- Patients who are currently receiving steroids at a dose of prednisone =< 5 mg daily (or equivalent) are permitted to enroll
- Patients who require topical, ophthalmologic and inhalational steroids are permitted to enroll
- Patients with hypothyroidism who are stable on hormone replacement are permitted to enroll
- Patients who require active immunosuppression with corticosteroids at a dose of prednisone > 5 mg daily (or equivalent) for any reason are ineligible
- Patients with adrenal insufficiency are ineligible
- Patients who have developed autoimmune disorders of grade 4 while on prior immunotherapy are not permitted to enroll on this study. Patients who developed autoimmune disorders of grade =< 3 may enroll if the disorder has resolved to grade =< 1 and the patient has been off systemic corticosteroids at doses > 5 mg for at least 2 weeks prior to randomization
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to randomization are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with a history of brain metastases are not eligible for this study as they do not meet the eligibility staging criteria
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have had an allogeneic tissue/solid organ transplant
-
Patient must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patient must not have severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
-
Patient must not have an active infection requiring systemic therapy
-
Patient must not have a known psychiatric or substance abuse disorder that would interfere with the patient's ability to cooperate with the requirements of the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Arm A (pembrolizumab)
NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase. ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial. |
Undergo biopsy
Ostatní jména:
Given IV
Ostatní jména:
Undergo collection of blood samples
Ostatní jména:
Undergo CT or PET/CT
Ostatní jména:
Undergo PET/CT
Ostatní jména:
Undergo surgery
Ostatní jména:
|
|
Experimentální: Arm B (CMP-001, pembrolizumab)
NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase. ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET/CT throughout the trial and may undergo optional biopsy at baseline and disease progression and optional collection of blood samples throughout the trial. |
Undergo biopsy
Ostatní jména:
Given IV
Ostatní jména:
Undergo collection of blood samples
Ostatní jména:
Undergo CT or PET/CT
Ostatní jména:
Undergo PET/CT
Ostatní jména:
Undergo surgery
Ostatní jména:
Given SC or intratumorally |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pathologic complete response rate
Časové okno: Up to 15 years
|
Will be estimated by the percentage of patients who achieve complete response, partial response or stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) and Immune-Modified RECIST criteria, with exact 90% confidence intervals. |
Up to 15 years
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Přežití bez relapsu
Časové okno: Od randomizace k relapsu nebo smrti (podle toho, co nastane dříve), hodnoceno do 15 let
|
Od randomizace k relapsu nebo smrti (podle toho, co nastane dříve), hodnoceno do 15 let
|
|
|
Celkové přežití
Časové okno: Od randomizace po smrt z jakékoli příčiny, hodnoceno do 15 let
|
Od randomizace po smrt z jakékoli příčiny, hodnoceno do 15 let
|
|
|
Radiographic response rate
Časové okno: Up to 15 years
|
Will be assessed using RECIST. |
Up to 15 years
|
|
Incidence of adverse events
Časové okno: Up to 30 days after the last study drug administration
|
Patients will be monitored for adverse events using the National Cancer Institute's Common Terminology Criteria for Adverse Events. |
Up to 30 days after the last study drug administration
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Ahmad Tarhini, ECOG-ACRIN Cancer Research Group
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary podle místa
- Novotvary
- Novotvary podle histologického typu
- Kožní choroby
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Neuroendokrinní nádory
- Nevi a melanomy
- Novotvary kůže
- Onemocnění kůže a pojivové tkáně
- Melanom
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Cytologické techniky
- Cytodiagnosis
- Diagnostické techniky, chirurgické
- Techniky chemie, analytické
- Analýza spektra
- Biopsie
- Manipulace se vzorkem
- Pembrolizumab
- Magnetická rezonanční spektroskopie
- Chirurgické postupy, operativní
Další identifikační čísla studie
Další identifikační čísla studie
- NCI-2020-14174
- U10CA180820 (Grant/smlouva NIH USA)
- NCI-2020-14174 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- EA6194 (Jiný identifikátor: CTEP)
- EA6194 (Jiný identifikátor: ECOG-ACRIN Cancer Research Group)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .